Premium
Questionable diagnostic benefit of the commercially available panel of bee venom components
Author(s) -
Arzt L.,
Bokanovic D.,
Schrautzer C.,
Schwarz I.,
Laipold K.,
Aberer W.,
Sturm G. J.
Publication year - 2017
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13154
Subject(s) - sensitization , medicine , allergen , allergy , immunology , bee venom , biology , zoology
For many years, only the major allergen rA pi m 1 has been available on the Immuno CAP system for routine diagnosis of bee venom ( BV ) allergy. Now, there are five components available, and we aimed to detect the sensitivity and specificity of rA pi m 1, 2, 3, 5, and 10 in BV ‐allergic patients. We further evaluated the sensitivity of rA pi m 1 and 2 of an alternative platform and investigated possible differences in the sensitization profile between monosensitization and clinically relevant double sensitization. Analysis of the whole panel of BV allergens of the CAP system still resulted in a lower sensitivity than analysis of the combination of rA pi m 1 and 2 of the Immulite (71.6% vs 85.8%). Sensitization rate of rA pi m 5 was more than doubled in double‐sensitized patients, while there was no difference for rApi m 2. The benefit of the commercially available panel of BV components is questionable, due to the insufficient sensitivity and still unavailable important cross‐reacting allergens.